"I'm afraid my emotions are too intense for other people... I get the impression that I'm exhausting to be around. But maybe I'm just exhausted with myself, because living inside my own head is tiring."
She's rehearsed this a hundred times. Laugh at the right moment, nod along, don't let anyone notice she's already lost the thread of what was just said. By the time the meeting ends, she's drained, not from the work itself, but from an hour spent performing "normal."
That quiet, exhausting effort is the part most people never picture when they hear "ADHD." A 2023 qualitative study exploring how young adults with the condition navigate relationships, stigma, and online support found a consistent pattern. Participants had felt "different" since childhood, and spent years building strategies to mask their symptoms, appearing to function normally at considerable emotional cost. One participant put it this way:
Forgetfulness and trouble concentrating were routinely read by others as irresponsibility or a lack of care, and even after a formal diagnosis, that judgment didn't always soften. A former colleague of mine fit this pattern almost exactly. She had ADHD, and for most of the time I knew her, it showed up in small ways: missed appointments, constant distraction, rapid speech. Yet she could also spend hours happily walking me through Goethe's biography or the symbolism running through Faust. For years, people around her read all of that as laziness or disinterest.
Online communities gave the study's participants something they didn't always get offline: a sense of belonging. However, that same connection came with a catch: misinformation from influencers who optimized for engagement rather than accuracy. That concern is reflected in the data.
ADHD medication is frequently discontinued. A study in The Lancet Psychiatry, tracking more than 1.2 million patients across eight countries, found that after one year, 47% of adolescents, 39% of young adults, and 48% of adults remained on medication. The reasons were mostly mundane: side effects, cost, and the difficulty of sticking with long-term treatment.
The problem is what fills the gap when people look for alternatives. My former colleague eventually stopped medication too, though her experience isn't representative of everyone with ADHD. It improved her concentration but left her feeling numb and disconnected. She tried everything from the relatively harmless, like art therapy, to the more concerning, like ayahuasca, which still lacks robust evidence of safety or efficacy for ADHD.
When Anecdotes Become Medical Advice
Increasingly, that search happens on social media, and it doesn't go well. A 2025 study published in PLOS ONE found that fewer than half the claims in the 100 most-viewed TikTok videos tagged #ADHD were consistent with current clinical evidence. Most videos focused on symptoms rather than treatment. While few made treatment-related claims, 88.8% promoted environmental modifications or behavioral strategies. The rest mentioned medication or workbooks, and notably, every reference to medication was negative, framed as something that makes people feel worse.
None of this shows that misinformation causes people to discontinue medication. The reasons they report are usually far more ordinary. What the TikTok data shows is narrower, but still telling. When medication appears in ADHD content online, it's rarely presented as a legitimate option; the alternatives usually come with no evidence at all, only reassurance and personal testimony.
The harder problem in sorting treatment truth from fiction comes from real, published research.
Studied Doesn't Mean Proven
One of the most common arguments from proponents of alternative medicine is that "there are studies" proving their interventions work for ADHD. That's technically true; researchers have investigated everything from supplements and herbal medicine to yoga, neurofeedback, and homeopathy. But that argument leans on a slippery equivalence. The existence of research is not the same as the existence of reliable evidence, and the gap between the two is often much wider than it looks.
That distinction is clear in a scoping review that identifies what researchers have already studied.
The review identified 133 studies published between 1979 and 2024, mostly from Asia and North America, covering mind-body interventions, nutritional supplements, herbal medicine, and dietary approaches. Based on this map, the authors suggested several therapies showed potential to improve inattention, impulsivity, hyperactivity, academic performance, and motor skills.
At first glance, that sounds encouraging. It shouldn't. Only 45 of the 133 studies were randomized clinical trials. The rest were observational studies, pilot studies, case reports, and narrative reviews (designs that can generate hypotheses but cannot establish causality).
Even randomized trials can mislead when their design has flaws baked in.
Why Study Design Matters More Than Study Count
A randomized, double-blind, placebo-controlled crossover trial evaluated homeopathic remedies for children with ADHD, finding lower symptom scores with homeopathic treatment than placebo, with improvements persisting at follow-up, is a good example. On paper, that looks like solid evidence. It isn't.
Before randomization, every participant went through an open-label homeopathy phase, and only those who responded advanced to the double-blind trial. This enriched enrollment design inflates the odds of a positive result by excluding nonresponders before the real test begins. The primary outcome relied on parental ratings, a subjective measure easily shaped by expectation, while the reported worsening after stopping homeopathy could just as easily reflect ADHD's natural fluctuations or regression to the mean. Strip away those design flaws, and there's very little left.
A Better Test Produces a Different Answer
A later trial, published in the Journal of Integrative and Complementary Medicine, makes the same point more directly. Researchers randomized 151 children with ADHD to homeopathic remedies plus consultations, the same consultations plus placebo, or usual care alone. The consultations consisted of 90-to-120-minute sessions covering symptoms, family routines, and school difficulties, repeated over roughly eight months. Children in both consultation groups improved over time, while those receiving usual care alone improved less, but there was no meaningful difference between homeopathy and placebo. In other words, the remedy wasn't doing the work. The consultation was.
The researchers themselves suggested that active listening and the therapeutic relationship explained the improvement better than any specific effect of the remedies. The "positive result" people cite for homeopathy was really a positive result for attention and empathy wearing a homeopathic label.
This illustrates a core principle of evidence-based medicine: improving during treatment doesn't mean the treatment caused the improvement. Attention, expectation, family adjustments, and regression to the mean can all move the needle on their own. That's why control groups, blinding, and randomization exist, and why a single trial, however well designed, rarely changes clinical practice. Findings need to be replicated and synthesized in systematic reviews and meta-analyses before they can be considered reliable.
Separating Promise from Proof
After hundreds of randomized controlled trials, the honest answer is a lot less exciting than influencers and alternative-medicine advocates suggest. It's worth stating plainly: medications remain the best-supported interventions for reducing core ADHD symptoms. Nothing else comes close on the current evidence. Among nonpharmacological strategies, a few show promise, but most rest on low- or very low-certainty evidence, which is a polite way of saying we still don't know whether they work.
That was the main conclusion of the umbrella review [1], published in the BMJ. The authors included only reviews from randomized controlled trials, reanalyzing 221 meta-analyses covering 31 interventions and 24 clinical outcomes across the lifespan, about 60% of which met high methodological-quality criteria. In other words, as rigorous a synthesis of the evidence as currently exists.
In children and adolescents, five medications showed significant improvement in core symptoms with at least moderate-certainty evidence [2], while in adults, only two medications plus cognitive behavioral therapy reached that same standard.
Nonpharmacological strategies told a more uneven story, with the certainty of the evidence heavily dependent on age. In adults, cognitive behavioral therapy was one of the few nonpharmacological approaches backed by at least moderate-certainty evidence. In children and adolescents, the same therapy, alongside acupuncture, showed large effects based only on low-certainty evidence. Mindfulness in adults, and exercise, neurofeedback, and zinc supplementation across age groups, produced statistically significant, sometimes large, effects, but nearly all of that evidence was low or very low certainty, meaning a handful of better-designed studies could overturn those findings.
In preschoolers, the picture was even starker. No nonpharmacological intervention reached moderate or high certainty, and almost none showed benefits that persisted over the medium or long term. One note of concern: researchers rarely reported safety data for these approaches, whereas “side effects” were generally well characterized. That asymmetry matters. The medications with the strongest evidence also tended to produce the most adverse events, reminding us that every prescribing decision involves weighing benefits against risks rather than choosing between something "good" and something "bad."
Complement Is Not a Substitute
None of this means nonpharmacological interventions are useless. Some may genuinely help specific patients, complement medication, improve quality of life, or provide practical tools for managing everyday challenges. What the evidence does not yet support is presenting them as reliable treatments by themselves for reducing core ADHD symptoms.
The problem, then, isn't that alternative treatments exist. It's what happens when they're marketed as substitutes for treatments with demonstrated efficacy, or sold as "natural cures" on the strength of evidence that wouldn't survive a closer look. Those claims shape real decisions, delaying effective treatment and leading people to invest time, money, and hope in approaches that look promising but remain far from proven.
[1] Umbrella reviews synthesize systematic reviews and meta-analyses.
[2] Methylphenidate, amphetamines, atomoxetine, alpha-2 agonists, and viloxazine
